- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Glenmark Therapeutics Inc., USA, has launched Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful, an over-the-counter product that compares to MiraLAX®. The OTC market for the 17-gram size of MiraLAX® generated approximately $555.7 million in annual sales according to Nielsen data for the past 52 weeks.
Marc Kikuchi, President & Business Head, North America, expressed excitement over this new offering, emphasizing Glenmark's commitment to providing high-quality solutions in response to growing market demand. This product launch positions Glenmark as a new supplier in a competitive segment, potentially enhancing its market share and revenue streams. Investors should watch closely for the impact of this launch on Glenmark's performance and market positioning in the OTC sector.